Skip to main content
AIDX
NASDAQ Industrial Applications And Services

20/20 BioLabs Secures $5M Private Placement, Boosts Cash to $4.2M Amidst Q1 Revenue Dip

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Neutral
Importance info
8
Price
$1.29
Mkt Cap
$13.519M
52W Low
$1.255
52W High
$50
52W Position info
2.8% above low
Off High info
97% below high
Rel. Volume info
0.2× avg
Market data snapshot near publication time

AIDX is trading near its 52-week low of $1.255 (2.8% above the low) on light trading volume (0.2× avg).

Summary

20/20 BioLabs reported a Q1 revenue decline and increased net loss, but significantly improved its cash position to $4.2 million via a $5.0 million private placement, with future revenue growth anticipated from new programs.


Key Events · Financing and Capital Events · AIDX

  • Strengthened Cash Position

    Cash and cash equivalents increased to $4.2 million as of March 31, 2026, up from $1.0 million at year-end 2025, primarily due to a $5.0 million private placement.

  • Significant Capital Facility Secured

    The $5.0 million private placement is part of a larger preferred purchase agreement that may provide up to $40.0 million in additional capital, subject to certain conditions.

  • Future Revenue Growth Drivers

    Q2 revenue is expected to benefit from Maryland's state-funded firefighter cancer screening program, and a second comparable state program is anticipated to contribute meaningfully to future revenue.

  • Q1 Financial Performance

    Reported Q1 2026 revenue of $0.4 million, down from $0.6 million in Q1 2025, with a net loss increasing to $2.2 million from $0.8 million, attributed to the timing of larger customer orders.


Analysis · AIDX · Industrial Applications And Services

This filing provides critical updates for 20/20 BioLabs, a company that previously disclosed a 'going concern' warning. While Q1 revenue declined and net loss increased, the company significantly strengthened its cash position to $4.2 million through a $5.0 million private placement. This capital infusion, part of a larger $40 million facility, is vital for extending the company's operational runway. Additionally, new state-funded programs and strategic partnerships are expected to drive future revenue growth, mitigating concerns from the recent financial performance.

At the time of this filing, AIDX was trading at $1.29 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $13.5M. The 52-week trading range was $1.26 to $50.00. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

AIDX - Latest Insights

AIDX
Aug 05, 2026, 12:00 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.4435
Real-time Price: $0.439 info
Change: -$0.0045 (-1%) info
Market Cap: $5.536M info
AIDX
Jul 22, 2026, 4:45 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.5381
Real-time Price: $0.439 info
Change: -$0.0991 (-18%) info
Market Cap: $5.536M info
AIDX
Jul 09, 2026, 4:01 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.6098
Real-time Price: $0.439 info
Change: -$0.1708 (-28%) info
Market Cap: $5.536M info
AIDX
Jul 01, 2026, 3:28 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.61565
Real-time Price: $0.439 info
Change: -$0.17665 (-29%) info
Market Cap: $5.536M info
AIDX
Jun 23, 2026, 5:02 PM EDT
Filing Type: DEF 14A
Importance Score:
9
Price at Filing: $0.6022
Real-time Price: $0.439 info
Change: -$0.1632 (-27%) info
Market Cap: $5.536M info